Immunohistochemical components, such as isocitrate dehydrogenase (IDH) mutations, GFAP (glial fibrillary acidic protein), ATRX (alpha-thalassemia/mental retardation, X-linked), and Ki-67, play a pivotal role in glioma diagnostic classification and risk stratification in prior literature. This evidence concerns the gene GFAP and alpha thalassemia spectrum.